| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Departments of Pathology [J. L., D-Q. G., M. K., W-H. W., M. F. P.], Preventive Medicine [D. T-W.], and Internal Medicine [S. R.] and the Norris Comprehensive Cancer Center [M. F. P.], University of Southern California Keck School of Medicine, Los Angeles, California 90033
mdm2 is part of a complex mechanism that regulates the expression of p53 as well as the function of Rb, p19ARF, and other genes. In humans, mdm2 dysregulation is associated with gene amplification. This study was undertaken to characterize altered mdm2 expression in a cohort of 38 invasive breast cancers and 9 normal breast specimens. Reverse-transcription PCR with primers spanning the entire open reading frame of the mdm2 gene in breast tissue RNA samples generated PCR products of full-length mdm2 (1526 bp) as well as smaller products (653, 281, 254, and 219 bp). Sequence analysis demonstrated that the 653-bp product was an alternatively spliced product (defined as splicing at the exon/intron boundary consensus sites), whereas the 281, 254, and 219 bp mdm2 products were aberrantly spliced products (splicing at sites not considered to be exon/intron boundary sites). Reverse-transcription-PCR with normal breast tissue RNA samples yielded only the 1526-bp product in five samples and the 1526-bp product and the 653-bp product in four samples. The 653-bp alternatively spliced product was expressed in 21% of breast cancers, and the smaller, aberrantly spliced mRNA products (281 bp, 254 bp, and/or 219 bp) were expressed in 16% of breast cancers. The protein products predicted by the alternatively spliced mRNAs and the aberrantly spliced mRNAs lacked either the entire binding domain for p53 or the majority of the binding domain for p53. Immunohistochemical analysis of HER2/neu (c-erbB2), estrogen receptor, progesterone receptor, epidermal growth factor receptor, and p53 protein was performed. p53 sequence alterations were identified by mismatch detection and confirmed by p53 oligonucleotide microarray technology. An association was demonstrated between the expression of aberrantly and/or alternatively spliced mdm2 mRNAs and a lack of progesterone receptor. An association was also demonstrated between mdm2 aberrantly and/or alternatively expression products and the presence of p53 tumor suppressor gene mutations. mdm2 is transcribed from two different promoters: one, p53-dependent, and the other, p53-independent. The 5' untranslated region of the transcripts was evaluated to determine the promoter usage in each breast cancer specimen. No correlation was observed between mdm2 splice products and promoter usage. The presence of aberrant expression products of mdm2 in breast cancer specimens was correlated with a shortened overall patient survival. These observations suggest that mdm2 expression is altered in invasive breast cancer and is associated with more aggressive disease.
This article has been cited by other articles:
|
|
 |
|
  E. L. Volk, L. Fan, K. Schuster, J. E. Rehg, and L. C. Harris The MDM2-A Splice Variant of MDM2 Alters Transformation In vitro and the Tumor Spectrum in Both Arf- and p53-Null Models of Tumorigenesis Mol. Cancer Res., June 1, 2009; 7(6): 863 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Lu, X. Feng, X. Man, G. Yang, L. Tang, D. Du, F. Zhang, H. Yuan, Q. Huang, Z. Zhang, et al. Aberrant Splicing of Hugl-1 Is Associated with Hepatocellular Carcinoma Progression Clin. Cancer Res., May 15, 2009; 15(10): 3287 - 3296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Xi, A. Feber, V. Gupta, M. Wu, A. D. Bergemann, R. J. Landreneau, V. R. Litle, A. Pennathur, J. D. Luketich, and T. E. Godfrey Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer Nucleic Acids Res., November 1, 2008; 36(20): 6535 - 6547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Schuster, L. Fan, and L. C. Harris MDM2 Splice Variants Predominantly Localize to the Nucleoplasm Mediated by a COOH-Terminal Nuclear Localization Signal Mol. Cancer Res., April 1, 2007; 5(4): 403 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Yang, C. S. Zong, W. Xia, Y. Wei, M. Ali-Seyed, Z. Li, K. Broglio, D. A. Berry, and M.-C. Hung MDM2 Promotes Cell Motility and Invasiveness by Regulating E-Cadherin Degradation. Mol. Cell. Biol., October 1, 2006; 26(19): 7269 - 7282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Dias, Y. Liu, A. Yau, L. Westrick, and S. C. Evans Regulation of hdm2 by Stress-Induced hdm2alt1 in Tumor and Nontumorigenic Cell Lines Correlating with p53 Stability Cancer Res., October 1, 2006; 66(19): 9467 - 9473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Chandler, R. K. Singh, L. C. Caldwell, J. L. Bitler, and G. Lozano Genotoxic Stress Induces Coordinately Regulated Alternative Splicing of the p53 Modulators MDM2 and MDM4 Cancer Res., October 1, 2006; 66(19): 9502 - 9508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chen, A. K. Seth, and A. E. Aplin Genetic and Expression Aberrations of E3 Ubiquitin Ligases in Human Breast Cancer Mol. Cancer Res., October 1, 2006; 4(10): 695 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Srebrow and A. R. Kornblihtt The connection between splicing and cancer J. Cell Sci., July 1, 2006; 119(13): 2635 - 2641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. O. Watermann, Y. Tang, A. zur Hausen, M. Jager, S. Stamm, and E. Stickeler Splicing Factor Tra2-{beta}1 Is Specifically Induced in Breast Cancer and Regulates Alternative Splicing of the CD44 Gene. Cancer Res., May 1, 2006; 66(9): 4774 - 4780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Agrawal and C. Eng Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer Hum. Mol. Genet., March 1, 2006; 15(5): 777 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Conde, R. Paniagua, J. Zamora, M. J. Blanquez, B. Fraile, A. Ruiz, and M. I. Arenas Influence of thyroid hormone receptors on breast cancer cell proliferation Ann. Onc., January 1, 2006; 17(1): 60 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Adamia, T. Reiman, M. Crainie, M. J. Mant, A. R. Belch, and L. M. Pilarski Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma Blood, June 15, 2005; 105(12): 4836 - 4844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zhou, R. Frum, S. Deb, and S. P. Deb The Growth Arrest Function of the Human Oncoprotein Mouse Double Minute-2 Is Disabled by Downstream Mutation in Cancer Cells Cancer Res., March 1, 2005; 65(5): 1839 - 1848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Q. Wang, J. M. Luk, P. P. Leung, B. W. Wong, E. J. Stanbridge, and S. T. Fan Alternative mRNA Splicing of Liver Intestine-Cadherin in Hepatocellular Carcinoma Clin. Cancer Res., January 15, 2005; 11(2): 483 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhang, H. Wang, G. Prasad, M. Li, D. Yu, J. A. Bonner, S. Agrawal, and R. Zhang Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models Clin. Cancer Res., February 15, 2004; 10(4): 1263 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Onel and C. Cordon-Cardo MDM2 and Prognosis Mol. Cancer Res., January 1, 2004; 2(1): 1 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bartel, L. C. Harris, P. Wurl, and H. Taubert MDM2 and Its Splice Variant Messenger RNAs: Expression in Tumors and Down-Regulation Using Antisense Oligonucleotides Mol. Cancer Res., January 1, 2004; 2(1): 29 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Fridman, E. Hernando, M. T. Hemann, E. de Stanchina, C. Cordon-Cardo, and S. W. Lowe Tumor Promotion by Mdm2 Splice Variants Unable to Bind p53 Cancer Res., September 15, 2003; 63(18): 5703 - 5706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T I Orban and E Olah Emerging roles of BRCA1 alternative splicing Mol. Pathol., August 1, 2003; 56(4): 191 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Huang, Z. Xing, Z. Luan, T. Wu, X. Wu, and G. Hu A Specific Splicing Variant of SVH, a Novel Human Armadillo Repeat Protein, Is Up-Regulated in Hepatocellular Carcinomas Cancer Res., July 1, 2003; 63(13): 3775 - 3782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bartl, J. Ban, H. Weninger, G. Jug, and H. Kovar A small nuclear RNA, hdm365, is the major processing product of the human mdm2 gene Nucleic Acids Res., February 15, 2003; 31(4): 1136 - 1147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Yang, S. Groshen, S. C. Formenti, N. E. Davidson, and M. F. Press P7 Antigen Expression in Human Breast Cancer Clin. Cancer Res., January 1, 2003; 9(1): 201 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Alarcon-Vargas and Z.'e. Ronai p53-Mdm2--the affair that never ends Carcinogenesis, April 1, 2002; 23(4): 541 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-M. F. Kersemaekers, F. Mayer, M. Molier, P. C. van Weeren, J. W. Oosterhuis, C. Bokemeyer, and L. H.J. Looijenga Role of P53 and MDM2 in Treatment Response of Human Germ Cell Tumors J. Clin. Oncol., March 15, 2002; 20(6): 1551 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dang, M.-L. Kuo, C. M. Eischen, L. Stepanova, C. J. Sherr, and M. F. Roussel The RING Domain of Mdm2 Can Inhibit Cell Proliferation Cancer Res., February 1, 2002; 62(4): 1222 - 1230. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
